Dogwood Therapeutics Inc
DWTX
Company Profile
Business description
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Contact
44 Milton Avenue
AlpharettaGA30009
USAT: +1 866 620-8655
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
12
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,467.00 | 4.40 | 0.05% |
| CAC 40 | 7,850.10 | 106.35 | 1.37% |
| DAX 40 | 23,566.54 | 67.22 | 0.29% |
| Dow JONES (US) | 42,140.15 | 890.77 | 2.16% |
| FTSE 100 | 8,604.98 | 50.18 | 0.59% |
| HKSE | 23,549.46 | 681.72 | 2.98% |
| NASDAQ | 18,583.68 | 654.77 | 3.65% |
| Nikkei 225 | 37,644.26 | 140.93 | 0.38% |
| NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
| S&P 500 | 5,806.87 | 146.96 | 2.60% |
| S&P/ASX 200 | 8,233.50 | 2.30 | 0.03% |
| SSE Composite Index | 3,369.24 | 27.25 | 0.82% |